Browse > Article
http://dx.doi.org/10.4142/jvs.2021.22.e79

Investigation of serum survivin in dogs suffering from cancer: a multicenter study  

Estaller, Annkathrin (Small Animal Clinic, Institute of Veterinary Medicine, Georg-August University of Gottingen)
Kessler, Martin (Small Animal Clinic Hofheim)
Wehrend, Axel (Clinic of Obstetrics, Gynaecology and Andrology of Large and Small Animals of the Justus-LiebigUniversity Giessen)
Gessler, Frank (Miprolab GmbH)
Hirschberger, Johannes (Clinic of Small Animal Medicine, Ludwig Maximilian University of Munich)
Neumann, Stephan (Small Animal Clinic, Institute of Veterinary Medicine, Georg-August University of Gottingen)
Publication Information
Journal of Veterinary Science / v.22, no.6, 2021 , pp. 79.1-79.14 More about this Journal
Abstract
Background: In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool. Objectives: This study examined whether survivin could be suitable as a potential canine serum tumor marker. Methods: This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17). Results: Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively). Conclusions: The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.
Keywords
Biomarker; dog; malignancy; serum; survivin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chen G. The relationship between the expression of TAM, survivin and the degree of necrosis of the tumor after cisplatin treatment in osteosarcoma. Eur Rev Med Pharmacol Sci. 2017;21(3):490-497.
2 Lodi G, Franchini R, Bez C, Sardella A, Moneghini L, Pellegrini C, et al. Detection of survivin mRNA in healthy oral mucosa, oral leucoplakia and oral cancer. Oral Dis. 2010;16(1):61-67.   DOI
3 Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology. 2007;54(79):2040-2044.
4 Yamada T, Fujita M, Kitao S, Ashida Y, Nishizono K, Tsuchiya R, et al. Serum alpha-fetoprotein values in dogs with various hepatic diseases. J Vet Med Sci. 1999;61(6):657-659.   DOI
5 Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem. 2007;22(1):57-60.   DOI
6 Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol. 2005;247:35-88.   DOI
7 Jena SC, Shrivastava S, Saxena S, Kumar N, Maiti SK, Mishra BP, et al. Surface plasmon resonance immunosensor for label-free detection of BIRC5 biomarker in spontaneously occurring canine mammary tumours. Sci Rep. 2019;9(1):13485.   DOI
8 Gunaldi M, Isiksacan N, Kocoglu H, Okuturlar Y, Gunaldi O, Topcu TO, et al. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther. 2018;14(3):570-573.   DOI
9 Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48(1):117-131.   DOI
10 Wang YR, Yan JX, Wang LN. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J Cancer Res Ther. 2014;10 Suppl:307-309.   DOI
11 Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008;17(9):1624-1629.   DOI
12 Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci. 2019;132(7):jcs223826.   DOI
13 Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99(7):4349-4354.   DOI
14 Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152(1):43-49.
15 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-921.   DOI
16 Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet. 1999;23(4):387-388.
17 Gravina G, Wasen C, Garcia-Bonete MJ, Turkkila M, Erlandsson MC, Toyra Silfversward S, et al. Survivin in autoimmune diseases. Autoimmun Rev. 2017;16(8):845-855.   DOI
18 Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Krol M, Jurka P. Current biomarkers of canine mammary tumors. Acta Vet Scand. 2018;60(1):66.   DOI
19 Henry CJ. Biomarkers in veterinary cancer screening: Applications, limitations and expectations. Vet J. 2010;185(1):10-14.   DOI
20 Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014;14(1):176.   DOI
21 Lechowski R, Jagielski D, Hoffmann-Jagielska M, Zmudzka M, Winnicka A. Alpha-fetoprotein in canine multicentric lymphoma. Vet Res Commun. 2002;26(4):285-296.   DOI
22 Hoo ZH, Candlish J, Teare D. What is an ROC curve? Emerg Med J. 2017;34(6):357-359.   DOI
23 Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, et al. The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol. 2007;171(5):1483-1498.   DOI
24 Tango Y, Kano R, Maruyama H, Asano K, Tanaka S, Hasegawa A, et al. Detection of autoantibodies against survivin in sera from cancer dogs. J Vet Med Sci. 2010;72(7):917-920.   DOI
25 Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66(20):10100-10111.   DOI
26 Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.   DOI
27 Shoeneman JK, Ehrhart EJ 3rd, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res. 2012;72(1):249-259.   DOI
28 Sharma S. Tumor markers in clinical practice: general principles and guidelines. Indian J Med Paediatr Oncol. 2009;30(1):1-8.   DOI
29 Carvalho MI, Pires I, Prada J, Queiroga FL. A role for T-lymphocytes in human breast cancer and in canine mammary tumors. BioMed Res Int. 2014;2014:130894.   DOI
30 Veiga GLD, Silva RDMD, Pereira EC, Azzalis LA, Alves BDCA, Gehrke FS, et al. The role of survivin as a biomarker and potential prognostic factor for breast cancer. Rev Assoc Med Bras (1992). 2019;65(6):893-901.   DOI
31 Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001;76(3):169-173.   DOI
32 Soltani K. Alpha-fetoprotein: a review. J Invest Dermatol. 1979;72(5):211-213.   DOI
33 Altieri DC, Marchisio PC. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79(11):1327-1333.
34 Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087-1098.   DOI
35 Harting T, Stubbendorff M, Willenbrock S, Wagner S, Schadzek P, Ngezahayo A, et al. The effect of dichloroacetate in canine prostate adenocarcinomas and transitional cell carcinomas in vitro. Int J Oncol. 2016;49(6):2341-2350.   DOI
36 Kavya N, Rao S, Sathyanarayana ML, Narayanaswamy HD, Byregowda SM, Ranganath L, et al. Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance. Vet World. 2017;10(10):1286-1291.   DOI
37 Yamazaki H, Takagi S, Hoshino Y, Hosoya K, Okumura M. Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines. PLoS One. 2013;8(11):e79810.   DOI
38 Mobasheri A, Cassidy JP. Biomarkers in veterinary medicine: Towards targeted, individualised therapies for companion animals. Vet J. 2010;185(1):1-3.   DOI
39 Senhorello ILS, Terra EM, Sueiro FAR, Firmo BF, Anai LA, Goloni C, et al. Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches. Vet Comp Oncol. 2020;18(3):315-323.   DOI
40 Hu J, Wang N, Yang Y, Ma L, Han R, Zhang W, et al. Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma. BMC Gastroenterol. 2018;18(1):186.   DOI